{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:17:35Z","timestamp":1779887855718,"version":"3.53.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic mechanism leading to PE during nilotinib therapy is still unknown and its management has not yet been defined. To the best of our knowledge, only a limited number of similar case reports have already been reported in the literature so far. Here, we describe the case of a 41-year-old CML patient who developed PE during first-line nilotinib, successfully treated with steroids and nilotinib permanent discontinuation. We highlight the differences among our patient and the others, proposing therapeutic strategies to solve this rare but still possible AE, of which physicians should be aware.<\/jats:p>","DOI":"10.3389\/fonc.2022.1012268","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:24:38Z","timestamp":1663043078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event"],"prefix":"10.3389","volume":"12","author":[{"given":"Raffaella","family":"Pasquale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030515","article-title":"Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2225-1","article-title":"Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials","volume":"106","author":"Suh","year":"2017","journal-title":"Int J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-46","article-title":"The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib","volume":"2","author":"Masiello","year":"2009","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma. Myeloma Leuk"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00277-017-3144-1","article-title":"Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series","volume":"97","author":"Iurlo","year":"2018","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23938","article-title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA adverse event reporting system","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B17","unstructured":"Highlights of prescribing information, FDA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","article-title":"Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors","volume":"4","author":"Kelly","year":"2009","journal-title":"Targeting Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel src-abl inhibitor, against imatinib-resistant bcr-Abl1 neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13608","article-title":"Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy","volume":"106","author":"Cortes","year":"2021","journal-title":"Eur J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03802-y","article-title":"Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy","volume":"98","author":"Tiribelli","year":"2019","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1638210","article-title":"Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line","volume":"8","author":"Kreutzman","year":"2019","journal-title":"Oncoimmunology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2000279","DOI":"10.1183\/13993003.00279-2020","article-title":"Pulmonary complications of bcr-abl tyrosine kinase inhibitors","volume":"56","author":"Weatherald","year":"2020","journal-title":"Eur Respir J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212447530","article-title":"Successful treatment of nilotinib-induced pleural effusion with prednisone","volume":"19","author":"Chakraborty","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/203939","article-title":"Pleural effusion: a rare side effect of nilotinib\u2013a case report","volume":"2014","author":"Teke","year":"2014","journal-title":"Case Rep Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243671","article-title":"Severe pleural effusion associated with nilotinib for chronic myeloid leukemia: cross-intollerance with tyrosin kinase inhibitors","volume":"14","author":"Satoh","year":"2021","journal-title":"BMJ. Case Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the united states","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27625","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1012268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:24:42Z","timestamp":1663043082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1012268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":34,"alternative-id":["10.3389\/fonc.2022.1012268"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1012268","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"article-number":"1012268"}}